mPFS1 after first-line everolimus was longer (16.3 months) compared to sunitinib (9 months), this was not statistically significant ( p = 0.15). Sequential second-line treatment showed no difference in the mPFS2 ( p = 0.3). No difference in OS between the 2 groups was observed. Tolerability was better for everolimus compared to sunitinib. Conclusions : Treatment with sequential molecular target agents was well tolerated and associated with similar overall mPFS in both schemes of administration.

more »

... Larger prospective studies are required to investigate the long-term efficacy and sequence of administration of alternate therapy with molecular targeting agents in metastatic pNETs and their effect on OS.